<i>Anaerobutyricum soehngenii</i> improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes.

ABSTRACT: Anaerobutyricum soehngenii (previously Eubacterium hallii) is a butyrate-producing next-generation beneficial microbe generally recognized as safe. Several short-term intervention trials by A. soehngenii L2-7 have shown improvement of insulin sensitivity in prediabetic subjects and type 2 diabetes patients. To determine the long-term cardiometabolic benefits and safety, we performed a 3-month double-blind, randomized placebo-controlled intervention in 98 prediabetic insulin-resistant adults in Europe and U.S. with daily administration of encapsulated cells of A. soehngenii CH-106, a tetracycline-sensitive isogenic derivative of strain L2-7. Compared to placebo, A. soehngenii-treated subjects showed significantly reduced glycemic variability (1% reduction

SUBMITTER: Attaye I 

PROVIDER: S-EPMC12087665 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature